Navigation Links
Confirmation of Strong Growth Over the First Half of 2008
Date:8/1/2008

Record Revenue of EUR1.55 Million (+45.5% at Constant Forex)

Substantial Increase in Sales of the JAK2 Test: +169%

LUMINY, France, August 1 /PRNewswire-FirstCall/ -- IPSOGEN (Alternext - FR0010626028 - ALIPS), a pioneer and key player in the development and commercialization of molecular diagnostic tests for cancer, today announces its revenue for its first half to 30 June 2008.

(in thousands of 30 June 2007 30 June 2008 Variation Variation

euros)* at constant

forex

Revenue from products 879 1,415 +,61.2%

Revenue from services 218 137 -37.2%

Consolidated total 1,096 1,552 +41.6% + 45.6%

*non audited data, IFRS For the first half of 2008, revenue totaled EUR1.55 million versus EUR1.09 million for the same period of 2007, an increase of 45.5% at constant forex. At real currency rates, revenue growth was 41.6%.

Sales were up for IPSOGEN's entire portfolio of leukemia tests, but the JAK2 test recorded the most spectacular growth (+169%) despite the fact that this test only obtained CE certification towards the end of the period.

Vincent Fert, President and CEO, states: "We are very pleased with our achievements over this first half. The growth in activity was buoyant and in line with our expectations. These results confirm the potential of the JAK2 test in the diagnosis of myeloproliferative disorders and show that IPSOGEN's product portfolio is perfectly positioned to benefit from the molecular diagnosis of cancer market's very dynamic growth."

About IPSOGEN

IPSOGEN develops and markets molecular diagnostic assays for patients with cancer. With more than 60 products already used routinely in more than 50 countries for the diagnosis, prognosis and follow-up of thousands of patients with leukemia, IPSOGEN is now also targeting breast cancer with the aim of providing diagnostic information that has been inaccessible until now. IPSOGEN intends to establish itself as a world leader in the molecular diagnosis of cancer. The company is pursuing the development and promotion of diagnostic standards that have a significant impact on patients, medical professionals and society in general. IPSOGEN has a workforce of some 40 people in France and the United States.

Publication of results for the first half of 2008: 9 October 2008 (after market)


'/>"/>
SOURCE IPSOGEN
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
3. Strong Demand Pushes up Both Prices and Sales Volumes for Dragons Main Products
4. U-M research: New plastic is strong as steel, transparent
5. Nobel Award in Medicine Holds Strong Messsage for Animal Activists
6. Monsanto Sees Record Sales in Fiscal Year 2007; Seeds and Traits Business Contributes to Strong Fourth Quarter and Year-End Results
7. Gen-Probe Reports Strong Financial Results for Third Quarter 2007, Raises Full-Year Guidance for Earnings Per Share and Total Revenues
8. Cephalon Announces Strong Third Quarter Financial Results
9. Edwards Lifesciences Forecasts Strong Growth in 2008
10. Genoptix Reports Strong Financial Results For Third Quarter 2007
11. STALLERGENES: 2007: A Further Year of Strong Growth: Up 16%
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... , Feb 22, 2017 ... of the "Global Biological Crop Protection (Bio-Pesticide) Market-By Type, By ... (2016-2021)" report to their offering. ... Global Biological Crop Protection Market is forecasted ... The strong growth in biopesticide or biological crop protection market ...
(Date:2/22/2017)... 2017 Aethlon Medical, Inc. (Nasdaq: ... that validated the ability of the Aethlon Hemopurifier® to ... mortality in immune-suppressed sepsis patients and also contribute to ... objective of the study was to validate the ... (EBV) and Herpes Simplex virus 1 (HSV1) by the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Pharma and biotech ... as European director. Operating from Pennside’s Zurich headquarters, Pennside Partners, GmbH, Mr. Perkins ... Pennside after more than a decade with leading market research firm, GfK. He ...
(Date:2/22/2017)... TRIANGLE PARK, N.C., Feb. 22, 2017  United Therapeutics ... its financial results for the fourth quarter and ... 2016 financial results reflect continued growth as net ... million," said Martine Rothblatt, Ph.D., United Therapeutics, Chairman ... our ability to develop and advance our growing ...
Breaking Biology Technology:
(Date:1/23/2017)... , Jan. 23, 2017  The latest mobile ... smartphone prices have dropped dramatically. The quarterly average price ... 2013 to $276 in Q4 2016.  There are now ... price of $116, up from just 28 a year ... According to Maxine Most , Acuity Market ...
(Date:1/19/2017)... 2017 Sensory Inc ., a ... for consumer electronics, and i nnerCore ... cybersecurity solutions, today announced a global partnership that ... worldwide to bolster security of data sensitive mobile ... authentication platforms they offer, innerCore now offers its ...
(Date:1/13/2017)... Jan. 13, 2017 Sandata Technologies, LLC, ... the homecare industry, including Electronic Visit Verification™ (EVV™), ... Justin Jugs, as Senior Vice President of Product ... years of homecare experience to Sandata, where he ... plans to align Sandata,s suite of solutions with ...
Breaking Biology News(10 mins):